摘要
目的探讨TP方案化疗同步精确放疗治疗Ⅲ期食管癌的近期疗效、局部控制率、生存率及毒性反应。方法 60例Ⅲ期食管癌患者根据入选标准随机分组,30例进入精确放疗加紫杉醇联合顺铂化疗组(放化组),30例进入精确放疗组(单放组)。单放组采用精确放疗9,5%PTV 56～60GY/28～30次,每周5次。放化组:放疗从第1天即开始采用精确放疗,同时化疗:紫杉醇40mg/m2;第18、1、5d,DDP 30mg,第1～3d静脉滴注,每28d为1周期,共两周期。结果局部近期疗效放化组好于单放组(P<0.05)。放化组1、3年生存率分别为87.7%、47%,单放组分别为82.5%2、1%。两组1年生存率间无明显差异(P>0.05),但3年生存率间差异有统计学学意义(P<0.05)。毒副反应放化组高于单放组,但患者能够耐受。结论以TP方案化疗同步精确放疗治疗Ⅲ期食管癌近期疗效和局部控制率较好,能提高远期生存率可能,虽毒性反应增加但能耐受。
Objective To evaluate the short-term efficacy,local control rates,survival rates and toxicity of concurrent TP（Cisplatin and Paclitaxel） chemotherapy and precision radiotherapy for Stage Ⅲ esophageal carcinoma.Methods Sixty cases Stage Ⅲesophageal carcinoma patients were randomized in two groups：30 cases was concurrent precision radiotherapy and TP chemotherapy（named chemo-radiation group）;Another 30 cases was precision radiotherapy only（named radiotherapy group）.Radiotherapy patients were treated precision radiotherapy： 95%PTV 56-60GY/28-30 time,5 times per week.The chemo-radiation group was also treated the same radiotherapy,but concurrent chemotherapy： Paclitaxel 40mg/m2-d1,d8,d15;DDP 30mg d1 d2 d3,Intravenous drip,28 days is 1 period total 2 periods.Results For local short-term efficacy,the chemo-radiation group is better than radiotherapy group,there＇s a significant difference between two groups（P0.05）.For survival rates,1-year,3-year of chemo-radiation group and chemo-radiation group were 87.7%,47% and 82.5%,21%,the difference is not significant in 1-year survival rate（P0.05） but clearly significant in 3-year survival rates（P0.05）.For toxic reaction,chemo-radiation group is higher than that of radiotherapy group,but can be tolerated.Conclusions Concurrent TP（Cisplatin and Paclitaxel） chemotherapy and precision radiotherapy for stage Ⅲ esophageal carcinoma can improve the short-term efficacy and local control rate,then may improve the long-term survival rate,although increase the toxic reaction but can be tolerated.
出处
《医药论坛杂志》
2011年第23期34-36,共3页
Journal of Medical Forum
关键词
食管癌
紫杉醇
顺铂
精确放疗
Esophageal carcinoma
Cisplatin
Paclitaxel
Precision radiotherapy
